Clinical Trial Update: Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating neratinib's effect on live cell HER2 signaling in triple negative breast cancer contexts.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: West Cancer Center | Conditions: Triple Negative Breast Cancer, Early-stage Breast Cancer | Phase 2 | Status: UNKNOWN